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Introduction: Rheumatic heart disease presents further an increased mortality, although their 
prevalence in industrialized countries decreases. However, remains a current topic for the 
economically less developed regions with the ineffectiveness o f  preventive methods applied to 
microbial agents. European guidelines dedicated to the management o f  patients with rheumatic 
heart disease are limited to recommendations regarding patient education, disease prevention and 
behavior, and recommendations to anticoagulant therapy.
Purpose and Objectives: Estimation and evaluation o f  therapeutic efficacy o f  kinetotherapy 
in the complex treatment o f  patients with rheumatic heart disease.
Materials and methods: Our study is based on 61 patients with rheumatic heart disease who 
were investigated in the complex by tools objectification: oxygen saturation, PSQIII general 
satisfaction, global assessment by the patient and physician PGA / MDGA, were treated and 
trained. Only 38 o f  them received physical therapy.
Results: Our study relieved the predominance o f  women in 68.8%, mean age 54.6 years, 61% was 
noticed varying degrees o f  obesity, half o f  the patients present different degree o f disability and only 5 
patients are capable to working. Clinical dates attest different stages o f  dyspnea (100%), palpitations 
followed by 72.13% and 57.37% with fatigue. At baseline, heart failure prevalent NYHA class 111 
according to 64% and finally the 40% grade III and 42% grade II. The patients from the study with 
kinetotherapy appropriated necessary methods like (descending abdominal breathing / chest and climbing 
stairs, restoring elements o f  breath), and training self-management o f the disease. We evaluated the 
efficacy o f complex treatment in combination with kinetotherapy in patients with rheumatic heart disease 
and we proved the superiority versus no kinetotherapy, translated by reducing the degree o f  dyspnea 
100%, global assessment o f  disease by the patient 34.2 mm and physician 33.5 mm. Analysis o f  overall 
satisfaction by PSQIII caused an elevated issues and interpersonal communication, time spent with the 
doctor from the average values in the population, but financial problem persist.
Conclusion: Patients who received kinetotherapy prove the increased level o f  general 
satisfaction, the decrease o f  global assessment by patient and the increase o f  the compliance to the 
received treatment versus those without kinetotherapy demonstrated by functional methods.
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Introduction: In the structure o f  chronic diseases in children one o f  the first place takes the 
pathology o f  the digestive organs, one o f  which consist the pancreas gland disease incidence is 
increasing in all age groups. Treatment consists o f  a suppression effect o f the pancreatic enzymes by 
administering antienzymes, preventing infection (with antibiotics and reduce inflammation). It is 
administered selective spasmolytic: Diuspatalin, Buscopan or Spasmomen, administered at least 2-3 
weeks in pancreatitis. Antibiotics are administered in cases o f  toxic syndrome with fever, signs o f 
inflammation in blood test and in pancreas damage in association with respiratory diseases (acute 
bronchitis, pneumonia). Proton pump inhibitors: Omeprazole, Lansoprazole. Antacids, Maalox (dose 
depending on the age) x 3 times a day. Infusion therapy - S.5 % -10 % glucose, 0.9 % s.NaCl, s. Ringer. 
Fluids intravenous (i.v) is given for purposes o f  detoxification and hydro-electrolytic rebalancing.
Purpose and objectives: Targeted full analysis o f  efficacy o f  the treatment administered to 
children with acute pancreatitis (AP) and chronic pancreatitis (CP) in the acute phase.
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